BALAXI PHARMACEUTICALS LIMITED

rs,

Limited C, I~~_;_~~ Chinta Shalini Company Secretary Registered Office: 2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-Ill, Hy:forabad, Telangana, India - 500096. CIN:L251

400 billion

up for its product lines. 8 Global Footprint Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion 9 Key Milestones Started business supplying white labelled pr

6 billion

al Footprint Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion 9 Key Milestones Started business supplying white labelled products to customers in Africa Pr

42%

– Dominican Republic 14 FINANCIAL HIGHLIGHTS 15 Management’s Comments “Our revenue growth of 42% during Q1 is driven by strong volume contribution from Latin American markets. We have also derive

Rs. 85 crore

atin American markets where we are rapidly gaining visibility. The estimated project investment of Rs. 85 crore will be financed partly from internal accruals and a judicious mix of additional capital. With the

106%

yback apart from several strategic benefits for the business from this investment.” 42% Revenues 106% Gross Profit 21% EBITDA 32% Profit After Tax 50% Return on Equity Debt Free Ashish Maheshwari

21%

veral strategic benefits for the business from this investment.” 42% Revenues 106% Gross Profit 21% EBITDA 32% Profit After Tax 50% Return on Equity Debt Free Ashish Maheshwari Chairman & Manag

32%

egic benefits for the business from this investment.” 42% Revenues 106% Gross Profit 21% EBITDA 32% Profit After Tax 50% Return on Equity Debt Free Ashish Maheshwari Chairman & Managing Director

50%

usiness from this investment.” 42% Revenues 106% Gross Profit 21% EBITDA 32% Profit After Tax 50% Return on Equity Debt Free Ashish Maheshwari Chairman & Managing Director 16 Quarterly Financ

41.7%

% EBITDA EBITDA Margin % Profit After Tax PAT Margin % Earnings Per Share (INR) 82.78 34.52 41.7% 17.03 20.6% 14.15 17.1% 14.15 58.34 16.8 28.8% 12.55 21.5% 10.71 18.4% 10.71 YoY +41

20.6%

TDA Margin % Profit After Tax PAT Margin % Earnings Per Share (INR) 82.78 34.52 41.7% 17.03 20.6% 14.15 17.1% 14.15 58.34 16.8 28.8% 12.55 21.5% 10.71 18.4% 10.71 YoY +41.9% +105.5%

17.1%

Profit After Tax PAT Margin % Earnings Per Share (INR) 82.78 34.52 41.7% 17.03 20.6% 14.15 17.1% 14.15 58.34 16.8 28.8% 12.55 21.5% 10.71 18.4% 10.71 YoY +41.9% +105.5% 1,290 bps +35

“Over the medium term, Balaxi sees several new market opportunities opening up for its product lines.”

“Going forward, as business scales up, we expect a positive contribution to revenue growth as well as geographical diversification.”

“85 crore will be financed partly from internal accruals and a judicious mix of additional capital.”

Registered Office

1

Established operations

1

Expansion initiated

1

Registered Office

2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-Ill, Hy:forabad, Telangana, India - 500096. CIN:L25191TG1942PLC12'598 Phone: +91 40 23555300 I Email: info@balaxi.in I Website: www.balaxiphar11a.in Branded IPR-driven Pharma Player in Frontier Markets Q1FY23 Financial Results Disclaimer Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Balaxi Pharmaceuticals Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances. 2 Contents 04 Corporate Snapshot 15 Financial Highlights 21 Strat

Established operations

Guatemala (Latin America), Dominican Republic (Caribbean) and Angola (Africa) New operations: Honduras (Latin America)

Expansion initiated

El Salvador, Nicaragua, Ecuador, Chile (Latin America) Central African Republic, Zambia (Africa) Products Vast range of essential OTC medicines – with healthy mix of generics and branded generics 649 product registrations in five countries 625 registrations submitted or in the pipeline Supply Chain Outsourced production from WHO GMP certified plants in India, China and Portugal Establishing EU GMP compliant facilities in Hyderabad Distribution Deep presence through 37 warehouses and on-ground fleet support Transformation New initiatives strengthening functionality in supply chain, regulatory affairs and customer service Successful process being replicated in other frontier markets; expansion plans in other global markets over near to medium term Centralized digital procurement, regulatory management and customized CRM tools 5 Key Success Factors Market Selection Methodology  Focus on countries with high-potential economic growth framework  Identify non-English speaking countries with